



A CSR Initiative



# JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3<sup>rd</sup> Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India)

February 21, 2025

The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051.	The Manager Listing Agreement The BSE Limited Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
<b>Symbol; JAGSNPHARM</b>	<b>SCRIP Code: 507789</b>

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR")**

With reference to the above we wish to inform you that Company had received the warning letter dated February 05, 2025 from USFDA regarding observations during the inspection of contract manufacturing facility of Jagsonpal.

The details required in terms of Regulation 30 read with schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached.

For Jagsonpal Pharmaceuticals Limited

**Abhishek Joshi**  
**Company Secretary and Compliance Officer**

Ph.: +91 124 4406710; E-mail: [cs@jagsonpal.com](mailto:cs@jagsonpal.com); Website: [www.jagsonpal.com](http://www.jagsonpal.com)

CIN NO. L74899DL1978PLC009181

Regd. Office: T-210 J, Shahpur Jat, New Delhi - 110049 (India)



A CSR Initiative

**Annexure 1****Regulation 30 read with schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

S.No.	Particulars	Remarks
1.	Name of the Authority	USFDA
2.	Nature and details of the action(s) taken, initiated or order(s) passed;	Warning Letter
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	February 07, 2025
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed;	CGMP Deviation Establishment Registration and Drug listing violation
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	Sale of INR 3.5 Cr. (1.46% of sales) till date in current fiscal year  The company supplies only one OTC API to US and has zero pipeline of products.